Thank you.
It's great to have the two witnesses here before us today. It's very interesting. I'm particularly happy to see UBC represented, my alma mater, where I worked for many years.
I would like to start with Dr. Murphy. We have heard about and you mentioned some of the initiatives and innovations that came out of the pandemic. You mentioned AbCellera, and there is my friend Pieter Cullis and his work on lipid nanoparticles. I think Precision NanoSystems is developing those things.
Could you perhaps use those researchers and the companies that formed out of their research, and where they are headed now, as an example of how they did it? Did they do it right? Have you learned something from that process? It's something I think we should all be proud of, but one of the things we are concerned with here is keeping IP in Canada as much as possible.
Perhaps you could expand on that story and say what we learned and where we're headed.